|  Help  |  About  |  Contact Us

Publication : SOX17 enables immune evasion of early colorectal adenomas and cancers.

First Author  Goto N Year  2024
Journal  Nature Volume  627
Issue  8004 Pages  636-645
PubMed ID  38418875 Mgi Jnum  J:365803
Mgi Id  MGI:7660401 Doi  10.1038/s41586-024-07135-3
Citation  Goto N, et al. (2024) SOX17 enables immune evasion of early colorectal adenomas and cancers. Nature 627(8004):636-645
abstractText  A hallmark of cancer is the avoidance of immune destruction. This process has been primarily investigated in locally advanced or metastatic cancer(1-3); however, much less is known about how pre-malignant or early invasive tumours evade immune detection. Here, to understand this process in early colorectal cancers (CRCs), we investigated how naive colon cancer organoids that were engineered in vitro to harbour Apc-null, Kras(G12D) and Trp53-null (AKP) mutations adapted to the in vivo native colonic environment. Comprehensive transcriptomic and chromatin analyses revealed that the endoderm-specifying transcription factor SOX17 became strongly upregulated in vivo. Notably, whereas SOX17 loss did not affect AKP organoid propagation in vitro, its loss markedly reduced the ability of AKP tumours to persist in vivo. The small fraction of SOX17-null tumours that grew displayed notable interferon-gamma (IFNgamma)-producing effector-like CD8(+) T cell infiltrates in contrast to the immune-suppressive microenvironment in wild-type counterparts. Mechanistically, in both endogenous Apc-null pre-malignant adenomas and transplanted organoid-derived AKP CRCs, SOX17 suppresses the ability of tumour cells to sense and respond to IFNgamma, preventing anti-tumour T cell responses. Finally, SOX17 engages a fetal intestinal programme that drives differentiation away from LGR5(+) tumour cells to produce immune-evasive LGR5(-) tumour cells with lower expression of major histocompatibility complex class I (MHC-I). We propose that SOX17 is a transcription factor that is engaged during the early steps of colon cancer to orchestrate an immune-evasive programme that permits CRC initiation and progression.
Quick Links:
 
Quick Links:
 

Expression

Publication --> Expression annotations

 

Other

3 Bio Entities

0 Expression